Sotac Pharma NSE SME IPO review (Avoid)

Review By Dilip Davda on Mar 24, 2023

•    SPL is in the pharma/healthcare business with three of its subsidiaries.
•    It has posted growth in top lines, but bottom lines have seen inconsistency.
•    The loss for FY21 is a bit surprising and declining margins raise concern.
•    Based on FY23 annualized earnings, the issue appears exorbitantly priced. 
•    There is no harm in skipping this pricey issue. 

Sotac Pharmaceuticals Ltd. (SPL) belongs to the Sotac group which has a few subsidiaries having an interest in the pharma/healthcare segment. The company is in the business of manufacturing pharmaceutical products for different marketers on a loan license or contract manufacturing basis. Its business is majorly on principle to principle basis with different marketers. As of the date of this Red Herring Prospectus, SPL caters to 162 corporate clients on a loan licence and/or contract manufacturing basis. 

SPL has a 71% holding in SOTAC Healthcare Private Limited (SOTAC Healthcare), and 100% of SOTAC Research Private Limited (SOTAC Research), thus making them it's Subsidiary Companies. SOTAC Healthcare is engaged in the business of manufacturing Beta-lactam drugs. SOTAC Research is engaged in the business of pharma molecule research and development. SPL has recently started a new venture namely SOTAC Lifescience Private Limited (SOTAC Lifescience).  It holds 51% of the total paid-up capital of SOTAC Lifescience. SOTAC Lifescience is a newly incorporated company and will be engaged in the business of Manufacturing Nutraceuticals products and food products on a contract-manufacturing basis. SOTAC Lifescience is in process of setting up its manufacturing plant and yet not commenced commercial production.

Sotac group's past and present clientele includes renowned pharma marketers and manufacturers namely Cadila Pharma, J. B. Chemical, Lincoln Pharma, Intas Pharma, Viatris (Mylan), Makers (Ipca), Corona Remedies, Eris Lifesciences, Stride Pharma, Stallion Pharma, Acme Pharma, Olecare Pharma, Treatwell Pharma, Ronak Healthcare, Curever Pharma, Kentoss Pharma, Sunrest Pharma, Ishan Healthcare etc. As of the date of this Red Herring Prospectus, SPL has a total of 89 Employees, 145 contract workers, and 12 Housekeeping persons.

The company is coming out with a maiden IPO of 3000000 equity shares of Rs. 10 each via the book-building route. It has announced a price band of Rs. 105 - Rs.111 per share and mulls mobilizing Rs. 33.30 cr. at the upper cap of the price band. The issue opens for subscription on March 29, 2023, and will close on April 03, 2023. The minimum application to be made is for 1200 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. The issue constitutes 27.15% of the post-IPO paid-up capital of the company. After 150000 shares of market maker quota, from the net portion of the issue, SPL has allocated not more than 50% for QIB, not less than 15% for HNIs, and not less than 35% for Retail investors. 

From the net proceeds of the IPO fund, it will utilize Rs. 10.80 cr. for working capital, Rs. 7.00 cr. for investment in the subsidiary, Rs. 5.90 cr. for the upgradation/expansion of existing premises, and the balance for general corporate purposes. 

Beeline Capital Advisors Pvt. Ltd. is the sole Book Running Lead Manager and KFin Technologies Ltd. is the registrar of the issue. Sunflower Broking Pvt. Ltd. is the market maker for the company. 

Having issued the entire equity capital at par so far, the company has also issued bonus shares in the ratio of 5 for 2 in December 2022. The average cost of acquisition of shares by the promoters is Rs. 0.03. Rs. 3.09 and Rs. 3.18 per share. 

Post-IPO, SPL's current paid-up equity capital of Rs. 8.05 cr. will stand enhanced to Rs. 11.05 cr. Based on the upper cap of the price band of the IPO, the company is looking for a market cap of Rs. 122.66 cr. 

On the financial performance front, for the last three fiscals, SPL has (on a consolidated basis) posted a turnover/net profit - (loss) of Rs. 28.83 cr./ Rs. 0.09 cr. (FY20), Rs. 48.95 cr. / Rs. - (2.37) cr. (FY21), and Rs. 73.37 cr. / Rs. 2.88 cr. (FY22). For H1 of FY23 ended on September 30, 2022, it earned a net profit of Rs. 0.47 cr. on a turnover of Rs. 39.95 cr. Though its top line shows growth, its bottom line has marked inconsistency with a surprising loss for FY21. As of September 30, 2022, it has total borrowings of Rs. 21.86 cr., which raises concern (refer to page no. F34 of the offer document).

For the last three fiscals, SPL has (on a consolidated basis) reported an average EPS of Rs. 2.32 and an average RoNW of 43.47%. The issue is priced at a P/BV of 11.20 based on its NAV of Rs. 9.91 as of September 30, 2022. (Refer to page no. 20 of the offer document).

The offer document is silent on its NAV details as of September 30, 2022. (refer the page no. 102 of the offer document). Its PAT margins, RoE, and RoCE has marked rollercoaster rides for the reported period and raised concern (refer to page 104 of the offer document).

If we annualize FY23 earnings and attribute it to post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of around 132.14. Based on FY22 earnings the issue is at a P/E of 42.53. Thus the issue appears exorbitantly priced. 

The company has declared 20% dividends for FY22. It will adopt a prudent dividend policy post-listing, based on its financial performance and future prospects. (However, the offer document has garble data for this on page no. 188 of the offer document). 

As per the offer document, the company has shown Lincoln Pharmaceuticals as their listed peer. It is trading at a P/E of around 9.68 (as of March 24, 2023). However, they are not truly comparable on an apple-to-apple basis. 

This is the 11 mandate from Beeline Capital. Out of the last 10 listings, one IPO closed below the issue price on the listing date.

Conclusion / Investment Strategy

This pharma/healthcare segment company has marked wild fluctuations in its bottom lines for the reported periods. Based on FY23 annualized earnings, the issue appears exorbitantly priced. It is operating in a highly competitive and fragmented segment. SPL’s debt level is also higher and raises concerns. There is no harm in skipping this pricey bet.

Reviewer recommends Avoid to the issue.

Review By Dilip Davda on Mar 24, 2023

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: dilip_davda@rediffmail.com ).

Sotac Pharmaceuticals IPO FAQs

  1. 1. Why Sotac Pharmaceuticals IPO?

    The initial public offer (IPO) of Sotac Pharmaceuticals Limited offers an early investment opportunity in Sotac Pharmaceuticals Limited. A stock market investor can buy Sotac Pharmaceuticals IPO shares by applying in IPO before Sotac Pharmaceuticals Limited shares get listed at the stock exchanges. An investor could invest in Sotac Pharmaceuticals IPO for short term listing gain or a long term.

  2. 2. How is Sotac Pharmaceuticals IPO?

    Read the Sotac Pharmaceuticals IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Sotac Pharmaceuticals IPO what should investors do?

    Sotac Pharmaceuticals IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Sotac Pharmaceuticals IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Sotac Pharmaceuticals IPO good?

    Our recommendation for Sotac Pharmaceuticals IPO is to avoid.

  5. 5. Is Sotac Pharmaceuticals IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Sotac Pharmaceuticals IPO.

  6. 6. When will Sotac Pharmaceuticals IPO allotment status?

    The Sotac Pharmaceuticals IPO allotment status will be available on or around Apr 10, 2023. The allotted shares will be credited in demat account by Apr 12, 2023. Visit Sotac Pharmaceuticals IPO allotment status to check.

  7. 7. When will Sotac Pharmaceuticals IPO list?

    The Sotac Pharmaceuticals IPO will list on Thursday, April 13, 2023, at NSE SME.